An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma

Combination regimens with anti-CD20 agents may improve outcomes of patients with relapsed or refractory B-cell malignancies, but comparative clinical evidence is limited. This review assessed the published evidence on the efficacy of anti-CD20 monoclonal antibodies in combination with chemotherapy in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), or diffuse large B-cell lymphoma (DLBCL), using a rapid evidence assessment (REA) approach. MEDLINE ®, Embase® and the Cochrane Library were searched from January 1, 1997 to July 14, 2017 (English language only).
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Article Source Type: research